Evidence map›Paper›PMID 40715158›Full record

ArticleScientific reports2025

Oligomeric hyaluronic acid-modified liposomes effectively improved skin permeability and anti-ageing activity of ellagic acid.

Xiaojing Yang, Kaiyuan Miao, Zhiwei Chen, Yan Meng, Jie Xiang, Chiqing Chen, Xinyan Chen, Zhaohua Shi

Abstract read
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. LiposomalInternational journal of molecular sciences · 2026
    Article
  2. Review
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Xiaojing YangSchool of Pharmacy, Hubei University of Chinese Medicine, Wuhan, 430065, China.
Kaiyuan MiaoSchool of Pharmacy, Hubei University of Chinese Medicine, Wuhan, 430065, China.
Zhiwei ChenSchool of Pharmacy, Hubei University of Chinese Medicine, Wuhan, 430065, China.
Yan MengSchool of Pharmacy, Hubei University of Chinese Medicine, Wuhan, 430065, China.
Jie XiangWufeng Chicheng Biotech Co., Ltd, Yichang, 443400, China.
Chiqing ChenWufeng Chicheng Biotech Co., Ltd, Yichang, 443400, China. 153670858@qq.com.
Xinyan ChenSchool of Pharmacy, Hubei University of Chinese Medicine, Wuhan, 430065, China. chenxy_328@163.com.
Zhaohua ShiKey Laboratory of Resource and Chinese Medicine Compounding, Ministry of Education, Hubei University of Chinese Medicine, Wuhan, 430065, China. zhshi78@hbucm.edu.cn.

Funding

Hubei Province Key Resaerch and Development Project 2022BCA053University Level Key Project of Traditional Chinese Medicine 2022ZZXZ003
6 · The paper itself

Abstract

To overcome natural skin barrier, deliver ellagic acid (EA) to the dermis, and promote its anti-ageing efficacy, oligomeric hyaluronic acid (HA) modified EA-loaded liposomes (EA-HA-L) were constructed via self-synthesized different molecular weights of HA linked cholesterol (HA-Chol), and then the effect of HA molecular weight on the skin permeability of EA was explored to clarify the optimal molecular weight of HA with best transdermal delivery effectiveness. Finally, a series of in vitro and in vivo experiments were conducted to survey the transdermal mechanism, skin irritation, antioxidant, anti-photo ageing and antiwrinkle effects of EA-loaded liposomes modified with the optimal molecular weight of HA. The results showed that EA-HA-L had less than 200 nm particle size and high encapsulation efficiency. Among them, 5 kDa of oligomeric HA-modified liposomes (EA-HA5k-L) maximized the skin penetration and retention of EA and promoted the distribution width of EA in the skin far beyond the thickness of the epidermal layer, indicating its good ability to deliver EA to the dermis. EA-HA5k-L displayed uniformly sized nanosphere morphology and slow-release behavior in neutral and acidic environments that simulated skin. The transdermal mechanism of EA-HA5k-L was proven to be related to the loosening of the stratum corneum, reduction of calcium adhesion proteins, and recognition of CD44 receptor. EA-HA5k-L had no irritant effect on the chicken embryo chorioallantoic membrane, with an irritant index close to 0.9% NaCl. EA-HA5k-L not only improved the clearance rate of EA on DPPH and hydroxyl radicals but also elevated its inhibition effect on elastase. Significantly, compared to free EA and EA-loaded liposomes without oligomeric HA modification (EA-L), EA-HA5k-L significantly increased the cellular uptake of EA through receptor-mediated endocytosis, and effectively blocked the increase in metalloproteinase-1 (MMP-1) content and decrease in type I collagen content induced by UVB in human dermal fibroblasts (HDFs), demonstrating better anti-photo ageing effectiveness. Moreover, EA-HA5k-L upregulated the relative expression of the elastin gene and three types of type I collagen gene (col1a1a, col1a1b, and col1a2) in zebrafish, and its expression promotion rates in col1a1b, col1a2 and elastin were remarkably higher than those of free EA, EA-L, and acetyl hexapeptide-8 as positive control. Conclusively, EA-HA5k-L ameliorated the anti-ageing effectiveness of EA due to the successful transdermal delivery and efficient cellular uptake, and 5 kDa of oligomeric HA-modified liposomes may be a promising transdermal delivery carrier to overcome skin barrier and upgrade the application prospects of EA in anti-skin ageing.

Indexed as

Ellagic AcidHyaluronic AcidLiposomesSkinSkin AgingAdministration, CutaneousAnimalsHumansPermeabilitySkin AbsorptionZebrafishEllagic AcidHyaluronic AcidLiposomesAnti-ageingEllagic acidHyaluronic acid-modified cholesterolLiposomesSkin permeability

Identifiers

PMID40715158
PMCPMC12297256

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.